Very happy to have had accepted 2 abstracts for @AmerUrological AUA20 in Washington DC. I will present data on #HIVEC for HR-NMIBC in a Podium Session and on urine #biomarkers to predict BCG response in a Poster Session @Urologia12 @CombatCancer
Successful first CRS+ PRS+Agitation HIPEC Case at the Charlotte Maxeke Academic Hospital in Johannesburg with Dr.Fourie and her fantastic team! @CombatCancer @GECOP_ @ESSOnews @lionfourie @alarjosan
Intraperitoneal hyperthermic chemotherapy after cytoreduction in patie... @CombatCancer @ESSOnews @GECOP_
Intraperitoneal hyperthermic chemotherapy after cytoreduction in patients with peritoneal metastases from endometrial cancer. The next frontier?
Endometrial cancer is the most common malignancy of the female genital tract. For cancers detected at an advanced stage or intraperitoneal relapse, th...
HIVEC is next big step to prevent recurrence in superficial bladder cancer #HIVEC
HIVEC is next big step to prevent recurrence in superficial bladder cancer
Currently, bladder cancer in India is treated with Bacillus Calmette-Guerin (BCG) intravesical immunotherapy
Dr.Leony Fourie from Johannesburg, SA and our colleague Deleene from #Suremedical at a CRS+Lap PRS HIPEC case observation with Dr.Álvaro Arjona in Córdoba.Thank you @alarjosan !@CombatCancer @SPeritoneum @GECOP_ @ESSOnews #HIPEC #CRS #PRS
A great Training Day PRS HIPEC with our the fantastic team of our partner BIES in Ankara/ Turkey @CombatCancer #HIPEC #PRS #BIESSaglik
Great to be at #CFU2019 with our friends from @surgynal
Combat launches in Mexico!
¡Gracias por un congreso excelente en nuestra Mérida! #SMU19 #SMU2019 #UroSoMe #UroSoMeMexico @smumexico
Successful PRS HIPEC case in the Hospital Insular Las Palmas de Gran Canaria lead by Dr.Tomasetti @CombatCancer @GECOP_ @SPeritoneum @ESSOnews
Un equipo de cirujanos de SEOQ aplica una técnica quirúrgica pionera para tumores de ovario avanzado.
👏Dres. Lidia Rodriguez, Ángela Casado, Juanma Sánchez, Sebastián Rufián y @alarjosan del Hospital Universitario de Córdoba
El Reina Sofía aplica una técnica quirúrgica pionera para tumores de ovario avanzado
La cirugía, que ya se ha practicado en ocho casos con éxito, permite aumentar la supervivencia, reducir la morbilidad y agilizar la recuperación de...
@CombatCancer Enjoying Innovate UK annual review #ScaleUp2019 Great work #Innovateuk team. Proud to be one of the first companies in the scale up program. Good to see UKplc in good shape despite political turmoil. Still more needs to be done on funding scaling UK business.
@BAUNnurses Come and join us for the final day in Liverpool to learn more about #HIVEC #BAUN @CombatCancer
@CombatCancer #HIVEC#HIPEC Combat team looking forward to upcoming BAUN exhibition @BAUNnurses
40 patients took part in the study, split into two groups – one which received the HIVEC™ treatment prior to a resection of the bladder, and another which received HIVEC after resection of the bladder.
97% of the patients were able to complete the full course of HIVEC treatments, and the majority of participants responded well to the treatment and show low rates of recurrence. Furthermore, the majority of the side-effects were low grade and had very little effect on the treatment plan.
Click Here to read the full article
Click Here to read the interview with the research author